Valuation: Caplin Point Laboratories Limited

Market Cap 203B 2.11B 1.84B 1.7B 1.56B 2.96B 3.01B 20.32B 7.98B 99.17B 7.91B 7.74B 342B P/E 2026
17.9x
P/E 2027 * 28.5x
Enterprise Value 203B 2.11B 1.84B 1.7B 1.56B 2.96B 3.01B 20.32B 7.98B 99.17B 7.91B 7.74B 342B EV / Sales 2026
5.23x
EV / Sales 2027 * 8.16x
Free-Float
26.39%
Yield 2026 *
-
Yield 2027 * 0.15%
1 day+0.78%
1 week+5.72%
Current month+1.81%
1 month+13.03%
3 months+53.67%
6 months+44.09%
Current year+45.11%
1 week 2,563.15
Extreme 2563.15
2,700
1 month 2,325
Extreme 2325
2,700
Current year 1,502.45
Extreme 1502.45
2,700
1 year 1,502.45
Extreme 1502.45
2,700
3 years 825
Extreme 825
2,700
5 years 575
Extreme 575
2,700
10 years 180
Extreme 180
2,700
Manager TitleAgeSince
Chief Executive Officer 71 27/03/2015
Director of Finance/CFO - 18/02/2016
Chief Administrative Officer - -
Director TitleAgeSince
Chairman 73 26/01/2010
Director/Board Member - 04/11/2025
Director/Board Member 71 27/03/2015
Change 5-day change 1-year change 3-year change Capi.($)
+0.78%+5.72%+29.08%+225.40% 2.09B
-0.07%+3.28%+12.89%+81.75% 48.66B
+0.59%-1.21%+67.38%+116.30% 35.52B
-0.59%-0.16%-4.12%+38.67% 12.07B
-0.26%+0.51%+19.25%+93.82% 11.99B
+1.13%+1.15%+32.83%+126.50% 9.29B
-1.76%-5.73%+41.23%-7.49% 6.92B
+0.50%+0.58%+19.74%+38.26% 7B
-0.46%+2.84%+2.73%+225.72% 6.74B
+7.04%+14.92%-10.65%+29.12% 6.36B
Average +0.67%+1.87%+21.04%+96.80% 14.66B
Weighted average by Cap. +0.35%+1.33%+26.88%+90.49%

Financials

2026 2027 *
Net sales 21.28B 221M 193M 179M 164M 310M 315M 2.13B 836M 10.39B 829M 811M 35.87B 24.88B 258M 226M 209M 192M 362M 369M 2.49B 978M 12.15B 970M 948M 41.95B
Net income 6.16B 63.95M 55.9M 51.69M 47.44M 89.78M 91.34M 616M 242M 3.01B 240M 235M 10.39B 7.13B 73.97M 64.66M 59.79M 54.87M 104M 106M 713M 280M 3.48B 278M 272M 12.02B
Net Debt - -
Logo Caplin Point Laboratories Limited
Caplin Point Laboratories Limited is an India-based pharmaceutical company with a business model catering predominantly to emerging markets of Latin America and Africa. The Company has also entered regulated markets such as the United States through its Subsidiary, Caplin Steriles Limited. The Company's operations include research & development and manufacturing of finished formulations, active pharmaceutical ingredients (APIs), clinical research, front-end generic presence in Latin America, brand marketing in Francophone Africa and a USFDA/EU-GMP approved injectable facility. In the Regulated Markets, its products include liquid & lyophilized vials, pre-filled syringes, three-pc ophthalmic droppers and pre-mix bags. In the Emerging Markets, its products include tablets, dry syrups - bottles, soft gels, capsules, suppositories, liquid syrups - bottles, liquid injectables in ampoules & vials, lyophilized vials, prefilled syringes (PFS), and emulsion injection in ampoules & vials.
Employees
3,966
Date Price Change Volume
16/07/26 2,671.70 +0.78% 19,698
15/07/26 ₹2,651.05 -0.26% 5,869
14/07/26 ₹2,658.05 +1.57% 15,555
13/07/26 ₹2,616.90 +1.22% 14,576
10/07/26 ₹2,585.40 -1.34% 5,832
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2,671.70INR
Average target price
2,505.00INR
Spread / Average Target
-6.24%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CAPLIPOINT Stock